PT1454992E - KINASE-TEST OF ANAPLASTIC LYMPHOMA, REAGENTS AND COMPOSITIONS - Google Patents

KINASE-TEST OF ANAPLASTIC LYMPHOMA, REAGENTS AND COMPOSITIONS

Info

Publication number
PT1454992E
PT1454992E PT03005186T PT03005186T PT1454992E PT 1454992 E PT1454992 E PT 1454992E PT 03005186 T PT03005186 T PT 03005186T PT 03005186 T PT03005186 T PT 03005186T PT 1454992 E PT1454992 E PT 1454992E
Authority
PT
Portugal
Prior art keywords
reagents
compositions
kinase
test
anaplastic lymphoma
Prior art date
Application number
PT03005186T
Other languages
Portuguese (pt)
Inventor
Lorenzo A Pinna
Donella-Deana Arianna
Marin Oriano
Mologni Luca
Gunby Rosalind
Gambacorti Passerini Carlo
Scapozza Leonardo
Original Assignee
Ist Naz Stud Cura Dei Tumori
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ist Naz Stud Cura Dei Tumori filed Critical Ist Naz Stud Cura Dei Tumori
Publication of PT1454992E publication Critical patent/PT1454992E/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines having two or more nitrogen atoms in the same ring, e.g. oxadiazines
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Disclosed are methods for detecting ALK tyrosine kinase activity and for the identification of compounds that modulate ALK activity, peptide substrates, reagents and compositions thereof.
PT03005186T 2003-03-07 2003-03-07 KINASE-TEST OF ANAPLASTIC LYMPHOMA, REAGENTS AND COMPOSITIONS PT1454992E (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03005186A EP1454992B1 (en) 2003-03-07 2003-03-07 Anaplastic lymphoma kinase assay, reagents and compositions thereof

Publications (1)

Publication Number Publication Date
PT1454992E true PT1454992E (en) 2006-09-29

Family

ID=32798804

Family Applications (1)

Application Number Title Priority Date Filing Date
PT03005186T PT1454992E (en) 2003-03-07 2003-03-07 KINASE-TEST OF ANAPLASTIC LYMPHOMA, REAGENTS AND COMPOSITIONS

Country Status (15)

Country Link
US (1) US20070031907A1 (en)
EP (1) EP1454992B1 (en)
JP (1) JP2006519800A (en)
CN (1) CN100345978C (en)
AT (1) ATE328112T1 (en)
CA (1) CA2518094A1 (en)
CY (1) CY1106115T1 (en)
DE (1) DE60305634T2 (en)
DK (1) DK1454992T3 (en)
ES (1) ES2263862T3 (en)
HK (1) HK1068154A1 (en)
IL (1) IL170669A0 (en)
PT (1) PT1454992E (en)
SI (1) SI1454992T1 (en)
WO (1) WO2004079326A2 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2447359T3 (en) 2006-04-14 2016-02-08 Cell Signaling Technology Inc Genetic defects and mutated ALK kinase in human solid tumors
US8168383B2 (en) 2006-04-14 2012-05-01 Cell Signaling Technology, Inc. Gene defects and mutant ALK kinase in human solid tumors
EP2107054A1 (en) 2008-04-01 2009-10-07 Università Degli Studi Di Milano - Bicocca Antiproliferative compounds and therapeutic uses thereof
EP2274288A2 (en) 2008-04-24 2011-01-19 Incyte Corporation Macrocyclic compounds and their use as kinase inhibitors
EP2161271A1 (en) 2008-09-08 2010-03-10 Università Degli Studi Di Milano - Bicocca Alpha-carboline inhibitors of NMP-ALK, RET, and Bcr-Abl
WO2010085597A1 (en) 2009-01-23 2010-07-29 Incyte Corporation Macrocyclic compounds and their use as kinase inhibitors
ES2668775T3 (en) * 2009-06-10 2018-05-22 Chugai Seiyaku Kabushiki Kaisha Tetracyclic compounds
CN101955995B (en) * 2010-06-17 2013-06-26 江苏迈迪基因生物科技有限公司 Combined detection method and diagnostic kit of fusion genes related to lymphoma
US20120101108A1 (en) 2010-08-06 2012-04-26 Cell Signaling Technology, Inc. Anaplastic Lymphoma Kinase In Kidney Cancer
MY160110A (en) 2010-08-20 2017-02-28 Chugai Pharmaceutical Co Ltd Composition comprising tetracyclic compound
EP2847353B1 (en) 2012-05-10 2022-01-19 The General Hospital Corporation Methods for determining a nucleotide sequence
HUE040055T2 (en) 2012-09-25 2019-02-28 Chugai Pharmaceutical Co Ltd Ret inhibitor
WO2014128235A1 (en) 2013-02-22 2014-08-28 F. Hoffmann-La Roche Ag Methods of treating cancer and preventing drug resistance
CN106661612A (en) 2014-01-27 2017-05-10 通用医疗公司 Methods of preparing nucleic acids for sequencing
EP3135671B1 (en) 2014-04-25 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Novel crystal of tetracyclic compound
US10350214B2 (en) 2014-04-25 2019-07-16 Chugai Seiyaku Kabushiki Kaisha Preparation containing tetracyclic compound at high dose
TWI718102B (en) 2014-08-08 2021-02-11 日商中外製藥股份有限公司 Amorphous body of tetracyclic compound
JP6741596B2 (en) 2015-01-16 2020-08-19 中外製薬株式会社 Concomitant medication
AU2017328953B2 (en) 2016-09-15 2023-09-14 Archerdx, Llc Methods of nucleic acid sample preparation for analysis of cell-free DNA
JP6997772B2 (en) 2016-09-15 2022-01-18 アーチャーディーエックス， エルエルシー Nucleic acid sample preparation method
ES2940620T3 (en) 2016-11-02 2023-05-09 Archerdx Llc Nucleic Acid Sample Preparation Methods for Immune Repertoire Sequencing
IL281079B1 (en) 2018-09-04 2024-08-01 Chugai Pharmaceutical Co Ltd Method of producing a tetracyclic compound

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05126833A (en) * 1991-10-31 1993-05-21 Tosoh Corp Immunochemical measurement method of tyrosine quinase activity and kit therefor
AU4281393A (en) * 1992-04-10 1993-11-18 Dana-Farber Cancer Institute, Inc. Activation-state-specific phosphoprotein immunodetection
DE69326388T2 (en) * 1992-06-22 1999-12-30 Kyowa Hakko Kogyo Co., Ltd. Process for the preparation of staurosporine derivatives
GB9314271D0 (en) * 1993-07-09 1993-08-18 Inst Of Cancer The Research Cell growth factor receptors
JP3442784B2 (en) * 1993-11-23 2003-09-02 ジェネンテク，インコーポレイテッド Kinase receptor activation assay
US6001621A (en) * 1993-11-23 1999-12-14 Genetech, Inc. Protein tyrosine kinases
US5529925A (en) * 1993-12-03 1996-06-25 St. Jude Children's Research Hospital Nucleic acid sequences and fusion proteins present in human t(2;5) lymphoma
US5763198A (en) * 1994-07-22 1998-06-09 Sugen, Inc. Screening assays for compounds
US5759787A (en) * 1996-08-26 1998-06-02 Tularik Inc. Kinase assay
EP0979288A2 (en) * 1997-04-28 2000-02-16 Sugen, Inc. Diagnosis and treatment of phosphatase- or kinase-related disorders
EP1201668A4 (en) * 1999-07-13 2003-05-21 Kyowa Hakko Kogyo Kk Staurosporin derivatives

Also Published As

Publication number Publication date
CY1106115T1 (en) 2011-06-08
DK1454992T3 (en) 2006-10-02
DE60305634D1 (en) 2006-07-06
ATE328112T1 (en) 2006-06-15
EP1454992A1 (en) 2004-09-08
SI1454992T1 (en) 2006-10-31
CN1756850A (en) 2006-04-05
DE60305634T2 (en) 2006-09-21
HK1068154A1 (en) 2005-04-22
ES2263862T3 (en) 2006-12-16
CN100345978C (en) 2007-10-31
IL170669A0 (en) 2011-08-01
WO2004079326A3 (en) 2004-12-09
WO2004079326A2 (en) 2004-09-16
JP2006519800A (en) 2006-08-31
EP1454992B1 (en) 2006-05-31
US20070031907A1 (en) 2007-02-08
CA2518094A1 (en) 2004-09-16

Similar Documents

Publication Publication Date Title
IL170669A0 (en) Anaplastic lymphoma kinase assay, reagents and compositions thereof
WO2005111212A3 (en) Biological bar code
DK1706424T3 (en) FC region variants
WO2005028443A3 (en) Protein tyrosine kinase enzyme inhibitors
ATE269295T1 (en) BTK INHIBITORS AND METHODS OF IDENTIFICATION AND USE
ATE419253T1 (en) INHIBITORS OF THIENOPYRIDINE AND FUROPYRIDINE KINASE
DE60007095T2 (en) CALANOLIDE FOR INHIBITING BTK
WO2005012574A3 (en) Biological bar-code
DK1847611T3 (en) Rhamnose-inducible expression system
EP1700120A4 (en) Marker for neuromyelitis optica
BR0215360A (en) Indoline derivatives useful as protein kinase inhibitors
ATE494548T1 (en) PURIFICATION, CHARACTERIZATION AND RECOVERY OF A UBIQUITIN E3 LIGASE
HK1080074A1 (en) 4,6-diaminosubstituted-2-[oxy or aminoxy]-[1,3,5]triazines as protein tyrosine kinase inhibitors
WO2002047535A3 (en) High throughput assay to detect inhibitors of the map kinase pathway
ATE413884T1 (en) BETA-SECRETASE SUBSTRATE AND USE THEREOF
WO2004050842A3 (en) Atm kinase compositions and methods
WO2007033374A3 (en) Pharmaceutical compositions and methods using temozolomide and a protein kinase inhibitor
DE602006021548D1 (en) SPECIMEN LENS AND COATING OF A REACTION SURFACE
WO2002053743A3 (en) Mammalian tribbles signaling pathways and methods and reagents related thereto
MA29565B1 (en) COMBINATION OF PYRIMIDYLAMINOBENZAMIDE AND IMATINIB COMPOUNDS FOR TREATING OR PREVENTING PROLIFERATIVE DISEASES
DK1328657T3 (en) Process for detecting serine / threonine kinase activity
WO2005003388A3 (en) Fluorescence assays for nucleic acid polymerase activity
ATE447586T1 (en) FPRL1 LIGANDS AND THEIR USE
NO20013748L (en) New analysis
AU2003293303A1 (en) Screening assay for identifying agents that modulate pak kinase or cd45 tyrosine phosphatase activity